UA73177C2 - Condensed azepins derivatives and use thereof as antidiuretic agents - Google Patents
Condensed azepins derivatives and use thereof as antidiuretic agents Download PDFInfo
- Publication number
- UA73177C2 UA73177C2 UA20021210560A UA20021210560A UA73177C2 UA 73177 C2 UA73177 C2 UA 73177C2 UA 20021210560 A UA20021210560 A UA 20021210560A UA 20021210560 A UA20021210560 A UA 20021210560A UA 73177 C2 UA73177 C2 UA 73177C2
- Authority
- UA
- Ukraine
- Prior art keywords
- tetrahydro
- pharmaceutically acceptable
- acceptable salt
- tautomer
- compound according
- Prior art date
Links
- 229940124538 antidiuretic agent Drugs 0.000 title abstract description 4
- 239000003160 antidiuretic agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 150000001538 azepines Chemical class 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 54
- -1 2,6-difluorophenyl Chemical group 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 201000010064 diabetes insipidus Diseases 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 claims description 7
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 208000008967 Enuresis Diseases 0.000 claims description 6
- 206010046543 Urinary incontinence Diseases 0.000 claims description 6
- 206010029446 nocturia Diseases 0.000 claims description 6
- 208000005346 nocturnal enuresis Diseases 0.000 claims description 6
- 208000032843 Hemorrhage Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 208000034158 bleeding Diseases 0.000 claims description 5
- 230000000740 bleeding effect Effects 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 208000028235 central diabetes insipidus Diseases 0.000 claims description 5
- 208000004880 Polyuria Diseases 0.000 claims description 4
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- SEPCNFYUTXGKHU-UHFFFAOYSA-N methyl 4-[[2-chloro-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methylamino]-4-oxobutanoate Chemical compound C1=C(Cl)C(CNC(=O)CCC(=O)OC)=CC=C1C(=O)N1C2=CC=CC=C2CCCC1 SEPCNFYUTXGKHU-UHFFFAOYSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 abstract description 3
- 229940044601 receptor agonist Drugs 0.000 abstract description 3
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract description 2
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 130
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 67
- 239000000047 product Substances 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 239000003480 eluent Substances 0.000 description 62
- 238000003818 flash chromatography Methods 0.000 description 62
- 239000000741 silica gel Substances 0.000 description 62
- 229910002027 silica gel Inorganic materials 0.000 description 62
- 239000000243 solution Substances 0.000 description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 52
- 239000007787 solid Substances 0.000 description 50
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 27
- 229920006395 saturated elastomer Polymers 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000013504 emergency use authorization Methods 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 239000012634 fragment Substances 0.000 description 24
- 150000001412 amines Chemical class 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 19
- YXHDLKWTPVMIOH-UHFFFAOYSA-N 1,3-difluoro-2-isocyanatobenzene Chemical compound FC1=CC=CC(F)=C1N=C=O YXHDLKWTPVMIOH-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 150000003141 primary amines Chemical class 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 14
- 108010004977 Vasopressins Proteins 0.000 description 13
- 102000002852 Vasopressins Human genes 0.000 description 13
- 229960003726 vasopressin Drugs 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 12
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 12
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 12
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 12
- 229960004281 desmopressin Drugs 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 108010064245 urinary gonadotropin fragment Proteins 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 238000009835 boiling Methods 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000012047 saturated solution Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 230000002686 anti-diuretic effect Effects 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 235000013877 carbamide Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001665 trituration Methods 0.000 description 6
- RCVHOZZMHOQHCU-UHFFFAOYSA-N 2-benzoyl-1h-1-benzazepine-3-carbonitrile Chemical compound N#CC=1C=CC2=CC=CC=C2NC=1C(=O)C1=CC=CC=C1 RCVHOZZMHOQHCU-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 description 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- AEPMKKWNHSPYQQ-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)-2-benzoyl-1h-1-benzazepine-4-carboxylate Chemical compound NCC=1C(C(=O)OC(C)(C)C)=CC2=CC=CC=C2NC=1C(=O)C1=CC=CC=C1 AEPMKKWNHSPYQQ-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- LTRYUAZFLOGRLJ-UHFFFAOYSA-N 4-cyano-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1C#N LTRYUAZFLOGRLJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 208000027276 Von Willebrand disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003335 secondary amines Chemical group 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 3
- XTDMZEZDXXJVMK-UHFFFAOYSA-N 1,2,3,5-tetrahydro-1,5-benzodiazepin-4-one Chemical compound N1C(=O)CCNC2=CC=CC=C21 XTDMZEZDXXJVMK-UHFFFAOYSA-N 0.000 description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 2
- WFDUOXJKEHADRT-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine Chemical compound N1CCCNC2=CC=CC=C21 WFDUOXJKEHADRT-UHFFFAOYSA-N 0.000 description 2
- NCKZJIZULSGMIM-UHFFFAOYSA-N 2-(1,2,3,4-tetrahydro-1,5-benzodiazepin-5-yl)ethanol Chemical compound OCCN1CCCNC2=CC=CC=C12 NCKZJIZULSGMIM-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- NUOFIQOYJIFSEN-UHFFFAOYSA-N 2-cyano-1-sulfonylguanidine Chemical compound N#CN=C(N)N=S(=O)=O NUOFIQOYJIFSEN-UHFFFAOYSA-N 0.000 description 2
- JOMIIZUPURXKKZ-UHFFFAOYSA-N 2-fluoro-4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C(F)=C1 JOMIIZUPURXKKZ-UHFFFAOYSA-N 0.000 description 2
- ALFWHEYHCZRVLO-UHFFFAOYSA-N 2-fluoro-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(F)=C1 ALFWHEYHCZRVLO-UHFFFAOYSA-N 0.000 description 2
- MVCVSUSTGSXJMZ-UHFFFAOYSA-N 3-benzoyl-1h-1,2-benzodiazepine-4-carbonitrile Chemical compound N=1NC2=CC=CC=C2C=C(C#N)C=1C(=O)C1=CC=CC=C1 MVCVSUSTGSXJMZ-UHFFFAOYSA-N 0.000 description 2
- ZUNRWCIMDCYBIQ-UHFFFAOYSA-N 3-chloro-4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=C1Cl ZUNRWCIMDCYBIQ-UHFFFAOYSA-N 0.000 description 2
- BQRXBNDTGWZCBQ-UHFFFAOYSA-N 5-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydro-1,5-benzodiazepine Chemical compound C1CCNC2=CC=CC=C2N1CC1=CC=CN=C1 BQRXBNDTGWZCBQ-UHFFFAOYSA-N 0.000 description 2
- GYQZHYBZRITNRC-UHFFFAOYSA-N 5-ethyl-1,2,3,4-tetrahydro-1,5-benzodiazepine Chemical compound CCN1CCCNC2=CC=CC=C12 GYQZHYBZRITNRC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229940083335 Vasopressin agonist Drugs 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 125000002785 azepinyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- 235000001159 dosh Nutrition 0.000 description 2
- 244000245171 dosh Species 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZNOBKUONZMASH-UHFFFAOYSA-N methyl 1,6-dimethyl-2-oxopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C)N(C)C1=O VZNOBKUONZMASH-UHFFFAOYSA-N 0.000 description 2
- LLOLLEPUQXDZSG-UHFFFAOYSA-N methyl 2-fluoro-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1F LLOLLEPUQXDZSG-UHFFFAOYSA-N 0.000 description 2
- VPJNOBUHVFOGIO-UHFFFAOYSA-N methyl 4-(bromomethyl)-2-fluorobenzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1F VPJNOBUHVFOGIO-UHFFFAOYSA-N 0.000 description 2
- XTZCVWDSGCVDFI-UHFFFAOYSA-N methyl 4-(bromomethyl)-3-chlorobenzoate Chemical compound COC(=O)C1=CC=C(CBr)C(Cl)=C1 XTZCVWDSGCVDFI-UHFFFAOYSA-N 0.000 description 2
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 2
- IRQSKJQDKUAART-UHFFFAOYSA-N methyl 6-(bromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)N=C1 IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 2
- 229960001238 methylnicotinate Drugs 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- FUEFNUGYRWQHTH-UHFFFAOYSA-N (2-nitrophenyl)methanesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1CS(Cl)(=O)=O FUEFNUGYRWQHTH-UHFFFAOYSA-N 0.000 description 1
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
- LWQKMNJCJHJLJG-UHFFFAOYSA-N (3-nitro-1h-1-benzazepin-2-yl)-phenylmethanone Chemical compound N1C2=CC=CC=C2C=CC([N+](=O)[O-])=C1C(=O)C1=CC=CC=C1 LWQKMNJCJHJLJG-UHFFFAOYSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- DBSXNGIBAKYMSS-UHFFFAOYSA-N 1,3-difluoro-2-isothiocyanatobenzene Chemical compound FC1=CC=CC(F)=C1N=C=S DBSXNGIBAKYMSS-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- SLFNGVGRINFJLK-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methylbenzene Chemical compound CC1=CC=C(Br)C(F)=C1 SLFNGVGRINFJLK-UHFFFAOYSA-N 0.000 description 1
- NOHQUGRVHSJYMR-UHFFFAOYSA-N 1-chloro-2-isocyanatobenzene Chemical compound ClC1=CC=CC=C1N=C=O NOHQUGRVHSJYMR-UHFFFAOYSA-N 0.000 description 1
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- XDYHDIYQYUGFBR-UHFFFAOYSA-N 1h-1-benzazepine-2-carbonitrile Chemical compound N1C(C#N)=CC=CC2=CC=CC=C21 XDYHDIYQYUGFBR-UHFFFAOYSA-N 0.000 description 1
- AJUMGSLQADLWKL-UHFFFAOYSA-N 1h-azepine;hydrochloride Chemical compound Cl.N1C=CC=CC=C1 AJUMGSLQADLWKL-UHFFFAOYSA-N 0.000 description 1
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical class NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 description 1
- XSLBWZNMWUEVMS-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,5-benzothiazepine Chemical compound S1CCCNC2=CC=CC=C21 XSLBWZNMWUEVMS-UHFFFAOYSA-N 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- KCODIBSTKHUDGN-UHFFFAOYSA-N 2,6-dimethyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)benzonitrile Chemical compound CC1=C(C#N)C(C)=CC(C(=O)N2C3=CC=CC=C3CCCC2)=C1 KCODIBSTKHUDGN-UHFFFAOYSA-N 0.000 description 1
- UEYQJQVBUVAELZ-UHFFFAOYSA-N 2-Hydroxynicotinic acid Chemical compound OC(=O)C1=CC=CN=C1O UEYQJQVBUVAELZ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- AWUPOXDTNYSREU-UHFFFAOYSA-N 2-chloro-6-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pyridine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C(Cl)=N1 AWUPOXDTNYSREU-UHFFFAOYSA-N 0.000 description 1
- ACQXHCHKMFYDPM-UHFFFAOYSA-N 2-chloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C(Cl)=N1 ACQXHCHKMFYDPM-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- VDFGCBODBVCSRU-UHFFFAOYSA-N 2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)benzonitrile Chemical compound C1=C(C#N)C(C)=CC(C(=O)N2C3=CC=CC=C3CCCC2)=C1 VDFGCBODBVCSRU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- GYPOFOQUZZUVQL-UHFFFAOYSA-N 2h-isoquinolin-3-one Chemical compound C1=CC=C2C=NC(O)=CC2=C1 GYPOFOQUZZUVQL-UHFFFAOYSA-N 0.000 description 1
- LCFSFWODNXPKAF-UHFFFAOYSA-N 3-benzoyl-1,2-benzothiazepine-4-carbonitrile Chemical compound N=1SC2=CC=CC=C2C=C(C#N)C=1C(=O)C1=CC=CC=C1 LCFSFWODNXPKAF-UHFFFAOYSA-N 0.000 description 1
- QDSMPKJQLISGDU-UHFFFAOYSA-N 3-methyl-4-(1-methyl-3,4-dihydro-2h-1,5-benzodiazepine-5-carbonyl)benzonitrile;hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C)CCCN1C(=O)C1=CC=C(C#N)C=C1C QDSMPKJQLISGDU-UHFFFAOYSA-N 0.000 description 1
- PXJORRLYPIOVBW-UHFFFAOYSA-N 3-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)benzonitrile Chemical compound CC1=CC(C#N)=CC=C1C(=O)N1C2=CC=CC=C2CCCC1 PXJORRLYPIOVBW-UHFFFAOYSA-N 0.000 description 1
- ZCHUZLJPQSYVBU-UHFFFAOYSA-N 4-(1-ethyl-3,4-dihydro-2h-1,5-benzodiazepine-5-carbonyl)-2-methylbenzonitrile Chemical compound C12=CC=CC=C2N(CC)CCCN1C(=O)C1=CC=C(C#N)C(C)=C1 ZCHUZLJPQSYVBU-UHFFFAOYSA-N 0.000 description 1
- COLJFGGZBIINCA-UHFFFAOYSA-N 4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)benzonitrile Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(C#N)C=C1 COLJFGGZBIINCA-UHFFFAOYSA-N 0.000 description 1
- ZZHQBEKGYLSTNW-UHFFFAOYSA-N 4-(3,4-dihydro-2h-1,5-benzothiazepine-5-carbonyl)-2-methylbenzonitrile Chemical compound C1=C(C#N)C(C)=CC(C(=O)N2C3=CC=CC=C3SCCC2)=C1 ZZHQBEKGYLSTNW-UHFFFAOYSA-N 0.000 description 1
- JKIHDSIADUBKPU-UHFFFAOYSA-N 4-(aminomethyl)benzamide Chemical class NCC1=CC=C(C(N)=O)C=C1 JKIHDSIADUBKPU-UHFFFAOYSA-N 0.000 description 1
- QMAHVAFURJBOFV-UHFFFAOYSA-N 4-(bromomethyl)-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C([N+]([O-])=O)=C1 QMAHVAFURJBOFV-UHFFFAOYSA-N 0.000 description 1
- VBXJIMYZOVOXGB-UHFFFAOYSA-N 4-[1-(2-hydroxyethyl)-3,4-dihydro-2h-1,5-benzodiazepine-5-carbonyl]-2-methylbenzonitrile Chemical compound C1=C(C#N)C(C)=CC(C(=O)N2C3=CC=CC=C3N(CCO)CCC2)=C1 VBXJIMYZOVOXGB-UHFFFAOYSA-N 0.000 description 1
- QUGTXCFZVMNBQT-UHFFFAOYSA-N 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-3-nitrobenzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=C1[N+]([O-])=O QUGTXCFZVMNBQT-UHFFFAOYSA-N 0.000 description 1
- QGLAYJCJLHNIGJ-UHFFFAOYSA-N 4-bromo-2,6-dimethylaniline Chemical compound CC1=CC(Br)=CC(C)=C1N QGLAYJCJLHNIGJ-UHFFFAOYSA-N 0.000 description 1
- LAYDFDMDUCVHBO-UHFFFAOYSA-N 4-bromo-2,6-dimethylbenzonitrile Chemical compound CC1=CC(Br)=CC(C)=C1C#N LAYDFDMDUCVHBO-UHFFFAOYSA-N 0.000 description 1
- AJRHGOBVXQIQRT-UHFFFAOYSA-N 4-bromo-2,6-dimethylbenzonitrile 4-cyano-3,5-dimethylbenzoic acid Chemical compound BrC1=CC(=C(C#N)C(=C1)C)C.C(#N)C1=C(C=C(C(=O)O)C=C1C)C AJRHGOBVXQIQRT-UHFFFAOYSA-N 0.000 description 1
- LPEBMDFRIKYFCF-UHFFFAOYSA-N 4-bromo-2-methylbenzonitrile Chemical compound CC1=CC(Br)=CC=C1C#N LPEBMDFRIKYFCF-UHFFFAOYSA-N 0.000 description 1
- SKXUZFJOLNNWIG-UHFFFAOYSA-N 4-bromo-3-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC=C1Br SKXUZFJOLNNWIG-UHFFFAOYSA-N 0.000 description 1
- NIDKGLRXRBFGEN-UHFFFAOYSA-N 4-cyano-2-methylbenzoic acid Chemical compound CC1=CC(C#N)=CC=C1C(O)=O NIDKGLRXRBFGEN-UHFFFAOYSA-N 0.000 description 1
- DNOXFFNRMSJGBK-UHFFFAOYSA-N 4-cyano-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1C#N DNOXFFNRMSJGBK-UHFFFAOYSA-N 0.000 description 1
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 description 1
- UEVUNFSJBRWHJW-UHFFFAOYSA-N 5-ethyl-2,3-dihydro-1H-1,5-benzodiazepin-4-one 1,2,3,5-tetrahydro-1,5-benzodiazepin-4-one Chemical compound O=C1CCNC2=C(N1)C=CC=C2.C(C)N2C(CCNC1=C2C=CC=C1)=O UEVUNFSJBRWHJW-UHFFFAOYSA-N 0.000 description 1
- HSZLNPJAFSBTOE-UHFFFAOYSA-N 5-ethyl-2,3-dihydro-1h-1,5-benzodiazepin-4-one Chemical compound N1CCC(=O)N(CC)C2=CC=CC=C21 HSZLNPJAFSBTOE-UHFFFAOYSA-N 0.000 description 1
- QTUHHZFSIDSGRC-UHFFFAOYSA-N 5-methyl-1,2,3,4-tetrahydro-1,5-benzodiazepine Chemical compound CN1CCCNC2=CC=CC=C12 QTUHHZFSIDSGRC-UHFFFAOYSA-N 0.000 description 1
- FAXYPRPMUNHQLC-UHFFFAOYSA-N 6-(aminomethyl)pyridine-3-carboxamide Chemical compound NCC1=CC=C(C(N)=O)C=N1 FAXYPRPMUNHQLC-UHFFFAOYSA-N 0.000 description 1
- HPTSHEHNJRDROJ-UHFFFAOYSA-N 6-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pyridine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=N1 HPTSHEHNJRDROJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTTZUVSONQLOEB-UHFFFAOYSA-N C(=O)(OC(C)(C)C)C1=C(C(=NNC2=C1C=CC=C2)C(C2=CC=CC=C2)=O)CN Chemical compound C(=O)(OC(C)(C)C)C1=C(C(=NNC2=C1C=CC=C2)C(C2=CC=CC=C2)=O)CN BTTZUVSONQLOEB-UHFFFAOYSA-N 0.000 description 1
- WDVUDBQMGRKEIG-UHFFFAOYSA-N CC(C)(C)OC(=O)C=1C=CNC(=O)C=1CN Chemical compound CC(C)(C)OC(=O)C=1C=CNC(=O)C=1CN WDVUDBQMGRKEIG-UHFFFAOYSA-N 0.000 description 1
- 102000017923 CHRM5 Human genes 0.000 description 1
- 101150064612 CHRM5 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000012988 Dithioester Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100310622 Mus musculus Soga1 gene Proteins 0.000 description 1
- DNDMYXXSVBVJFM-UHFFFAOYSA-N N#CC=1C=C2N=CC=CC=C2NC=1C(=O)C1=CC=CC=C1 Chemical compound N#CC=1C=C2N=CC=CC=C2NC=1C(=O)C1=CC=CC=C1 DNDMYXXSVBVJFM-UHFFFAOYSA-N 0.000 description 1
- 241000018242 Obba <basidiomycete fungus> Species 0.000 description 1
- 101710092453 Peptide hormone 2 Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 206010034962 Photopsia Diseases 0.000 description 1
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000159610 Roya <green alga> Species 0.000 description 1
- 101000715691 Sorangium cellulosum (strain So ce56) Multifunctional esterase Proteins 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 241000408184 Suada Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- ZLZJGPLFSNJRHW-UHFFFAOYSA-N [4-(aminomethyl)-2-methylphenyl]-(1-methyl-3,4-dihydro-2h-1,5-benzodiazepin-5-yl)methanone;hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C)CCCN1C(=O)C1=CC=C(CN)C=C1C ZLZJGPLFSNJRHW-UHFFFAOYSA-N 0.000 description 1
- SXBWEXABICFPHT-UHFFFAOYSA-N [4-(aminomethyl)-3-chlorophenyl]-(1-methyl-3,4-dihydro-2h-1,5-benzodiazepin-5-yl)methanone Chemical compound C12=CC=CC=C2N(C)CCCN1C(=O)C1=CC=C(CN)C(Cl)=C1 SXBWEXABICFPHT-UHFFFAOYSA-N 0.000 description 1
- UMNUBLZVWPGUNB-UHFFFAOYSA-N [N].N1C=CC=CC=C1 Chemical group [N].N1C=CC=CC=C1 UMNUBLZVWPGUNB-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- OUYYNZDOJHSQBW-UHFFFAOYSA-N cyanomethanimidamide Chemical compound NC(=N)C#N OUYYNZDOJHSQBW-UHFFFAOYSA-N 0.000 description 1
- SSGODMHQNTWPOX-UHFFFAOYSA-N cyanothiourea Chemical compound NC(=S)NC#N SSGODMHQNTWPOX-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005022 dithioester group Chemical group 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- DUVOZUPPHBRJJO-UHFFFAOYSA-N ethyl 2-isocyanatoacetate Chemical compound CCOC(=O)CN=C=O DUVOZUPPHBRJJO-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TYMKSZOFZPYQDI-UHFFFAOYSA-N methyl 2-(4-oxo-2,3-dihydro-1h-1,5-benzodiazepin-5-yl)acetate Chemical compound N1CCC(=O)N(CC(=O)OC)C2=CC=CC=C21 TYMKSZOFZPYQDI-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 1
- SHKDOGHJQHIIRD-UHFFFAOYSA-N methyl 2-chloro-6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C)N=C1Cl SHKDOGHJQHIIRD-UHFFFAOYSA-N 0.000 description 1
- KTFQDZCNPGFKAH-UHFFFAOYSA-N methyl 3-chloro-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(Cl)=C1 KTFQDZCNPGFKAH-UHFFFAOYSA-N 0.000 description 1
- JCAZSWWHFJVFPP-UHFFFAOYSA-N methyl 5-chloro-5-oxopentanoate Chemical compound COC(=O)CCCC(Cl)=O JCAZSWWHFJVFPP-UHFFFAOYSA-N 0.000 description 1
- UDAQXROOFWMMQD-UHFFFAOYSA-N methyl 6-(azidomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CN=[N+]=[N-])N=C1 UDAQXROOFWMMQD-UHFFFAOYSA-N 0.000 description 1
- XLRXQGFBMDNOTI-UHFFFAOYSA-N methyl 6-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CNC(=O)OC(C)(C)C)N=C1 XLRXQGFBMDNOTI-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- UJYAZVSPFMJCLW-UHFFFAOYSA-N n-(oxomethylidene)benzenesulfonamide Chemical compound O=C=NS(=O)(=O)C1=CC=CC=C1 UJYAZVSPFMJCLW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940127264 non-peptide agonist Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229910000065 phosphene Inorganic materials 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KWGFMMAPDMTJHX-UHFFFAOYSA-N sulfonylthiourea Chemical compound SC(=N)N=S(=O)=O KWGFMMAPDMTJHX-UHFFFAOYSA-N 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- HFOWWBNMJUVIMH-UHFFFAOYSA-N sulfuryl diisothiocyanate Chemical compound S=C=NS(=O)(=O)N=C=S HFOWWBNMJUVIMH-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- QVYPQUFLXNENML-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)-2-(pyridine-3-carbonyl)-1h-1-benzazepine-4-carboxylate Chemical compound NCC=1C(C(=O)OC(C)(C)C)=CC2=CC=CC=C2NC=1C(=O)C1=CC=CN=C1 QVYPQUFLXNENML-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CCGFWRGAUGPUBY-UHFFFAOYSA-N tert-butyl n-[[2-nitro-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]carbamate Chemical compound C1=C([N+]([O-])=O)C(CNC(=O)OC(C)(C)C)=CC=C1C(=O)N1C2=CC=CC=C2CCCC1 CCGFWRGAUGPUBY-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical class CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015601.8A GB0015601D0 (en) | 2000-06-26 | 2000-06-26 | Novel antidiuretic agents |
| PCT/GB2001/002737 WO2002000626A1 (en) | 2000-06-26 | 2001-06-21 | Fused azepine derivatives and their use as antidiuretic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73177C2 true UA73177C2 (en) | 2005-06-15 |
Family
ID=9894399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20021210560A UA73177C2 (en) | 2000-06-26 | 2001-06-21 | Condensed azepins derivatives and use thereof as antidiuretic agents |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7176195B2 (cs) |
| EP (1) | EP1294698B1 (cs) |
| JP (2) | JP3935071B2 (cs) |
| KR (1) | KR100805808B1 (cs) |
| CN (1) | CN1308313C (cs) |
| AT (1) | ATE368650T1 (cs) |
| AU (2) | AU7429001A (cs) |
| CA (1) | CA2412555A1 (cs) |
| CZ (1) | CZ304037B6 (cs) |
| DE (1) | DE60129697T2 (cs) |
| GB (1) | GB0015601D0 (cs) |
| HK (1) | HK1059780A1 (cs) |
| HU (1) | HU229315B1 (cs) |
| IL (1) | IL153358A0 (cs) |
| MX (1) | MXPA02012779A (cs) |
| NO (1) | NO324217B1 (cs) |
| NZ (1) | NZ523066A (cs) |
| PL (1) | PL359187A1 (cs) |
| RU (1) | RU2269517C2 (cs) |
| UA (1) | UA73177C2 (cs) |
| WO (1) | WO2002000626A1 (cs) |
| ZA (1) | ZA200300403B (cs) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| EP2426122A1 (en) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
| KR20050100615A (ko) | 2003-01-14 | 2005-10-19 | 싸이토키네틱스, 인코포레이티드 | 화합물, 조성물 및 방법 |
| WO2004089896A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| WO2004098751A1 (en) * | 2003-05-02 | 2004-11-18 | Worcester Polytechnic Institute | Composite gas separation modules having high tamman temperature intermediate layers |
| EP1512687A1 (en) * | 2003-09-05 | 2005-03-09 | Ferring B.V. | Piperazines as oxytocin agonists |
| DE60305043T2 (de) * | 2003-11-13 | 2006-11-30 | Ferring B.V. | Blisterverpackung und feste Dosierungsform enthaltend Desmopressin |
| WO2006009726A2 (en) | 2004-06-17 | 2006-01-26 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| EP1627876A1 (en) | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
| EP1632494A1 (en) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| CA2588768A1 (en) * | 2004-11-17 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| JP5301284B2 (ja) | 2005-12-15 | 2013-09-25 | サイトキネティクス・インコーポレーテッド | 特定の化学物質、組成物および方法 |
| US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
| WO2007078839A2 (en) * | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| SE528446C2 (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
| EA017249B8 (ru) * | 2007-05-10 | 2013-01-30 | Олбани Молекьюлар Рисерч, Инк. | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| KR101522747B1 (ko) | 2007-08-06 | 2015-05-26 | 알레간 인코포레이티드 | 데스모프레신 약물 전달을 위한 방법 및 장치 |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| CA2724653A1 (en) * | 2008-05-21 | 2009-11-26 | Ferring International Center S.A. | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| GB201005623D0 (en) | 2010-04-01 | 2010-05-19 | Vantia Ltd | New polymorph |
| EP2966061B1 (en) * | 2011-03-04 | 2017-05-03 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
| GB201105537D0 (en) | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN103159641A (zh) * | 2011-12-14 | 2013-06-19 | 天津泰普药品科技发展有限公司 | 托伐普坦中间体2-甲酸-5-(2-甲基苯甲酰氨基)甲苯的制备方法 |
| RU2480468C1 (ru) * | 2012-02-16 | 2013-04-27 | Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" | КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ ПАРА-МЕТОКСИАНИЛИДА 6-ГИДРОКСИ-4-ОКСО-2,4-ДИГИДРО-1Н-ПИРРОЛО[3,2,1-ij]ХИНОЛИН-5-КАРБОНОВОЙ КИСЛОТЫ |
| CN103373960B (zh) * | 2012-04-24 | 2017-03-01 | 江苏康缘药业股份有限公司 | 一种托伐普坦中间体及其制备方法 |
| WO2020154581A1 (en) * | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516774A (en) | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US6096735A (en) * | 1994-06-15 | 2000-08-01 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic derivatives |
| BR9811585A (pt) * | 1997-07-30 | 2000-09-26 | American Home Prod | Agonistas de vasopressinas tricìclicas |
| ES2229523T3 (es) | 1997-07-30 | 2005-04-16 | Wyeth | Agonistas triciclicos de la vasopresina. |
| GB2355454A (en) * | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
-
2000
- 2000-06-26 GB GBGB0015601.8A patent/GB0015601D0/en not_active Ceased
-
2001
- 2001-06-21 AU AU7429001A patent/AU7429001A/xx active Pending
- 2001-06-21 JP JP2002505374A patent/JP3935071B2/ja not_active Expired - Fee Related
- 2001-06-21 HU HU0301339A patent/HU229315B1/hu not_active IP Right Cessation
- 2001-06-21 US US10/311,301 patent/US7176195B2/en not_active Expired - Fee Related
- 2001-06-21 KR KR1020027017214A patent/KR100805808B1/ko not_active IP Right Cessation
- 2001-06-21 CZ CZ20024157A patent/CZ304037B6/cs not_active IP Right Cessation
- 2001-06-21 UA UA20021210560A patent/UA73177C2/uk unknown
- 2001-06-21 PL PL01359187A patent/PL359187A1/xx not_active IP Right Cessation
- 2001-06-21 NZ NZ523066A patent/NZ523066A/en not_active IP Right Cessation
- 2001-06-21 DE DE60129697T patent/DE60129697T2/de not_active Expired - Lifetime
- 2001-06-21 IL IL15335801A patent/IL153358A0/xx unknown
- 2001-06-21 RU RU2003101970/04A patent/RU2269517C2/ru not_active IP Right Cessation
- 2001-06-21 CA CA002412555A patent/CA2412555A1/en not_active Abandoned
- 2001-06-21 AU AU2001274290A patent/AU2001274290B9/en not_active Ceased
- 2001-06-21 CN CNB018118135A patent/CN1308313C/zh not_active Expired - Fee Related
- 2001-06-21 EP EP01940792A patent/EP1294698B1/en not_active Expired - Lifetime
- 2001-06-21 WO PCT/GB2001/002737 patent/WO2002000626A1/en active IP Right Grant
- 2001-06-21 AT AT01940792T patent/ATE368650T1/de not_active IP Right Cessation
- 2001-06-21 MX MXPA02012779A patent/MXPA02012779A/es active IP Right Grant
-
2002
- 2002-12-18 NO NO20026094A patent/NO324217B1/no not_active IP Right Cessation
-
2003
- 2003-01-15 ZA ZA200300403A patent/ZA200300403B/xx unknown
-
2004
- 2004-04-15 HK HK04102625A patent/HK1059780A1/xx unknown
-
2005
- 2005-01-19 JP JP2005011930A patent/JP2005104990A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73177C2 (en) | Condensed azepins derivatives and use thereof as antidiuretic agents | |
| DK2803662T3 (en) | P2X4 receptor antagonist | |
| CN106414408A (zh) | 缩合环吗啡喃和其用途 | |
| AU2001274290A1 (en) | Fused azepine derivatives and their use as antidiuretic agents | |
| KR101078076B1 (ko) | 1，2，4，5테트라히드로3ｈ벤즈아제핀 화합물, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 | |
| ES2239717T3 (es) | Agonistas de oxitocina. | |
| CZ20031311A3 (cs) | Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla) | |
| AU2855899A (en) | Amide derivatives and nociceptin antagonists | |
| US20040224967A1 (en) | Phenylaminopyrimidine derivatives and methods of use | |
| WO2007079239A2 (en) | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof | |
| CA2396277C (en) | Condensed azepines as vasopressin agonists | |
| CA2536313A1 (en) | Fused pyrimidine derivative and use thereof | |
| WO2009137492A1 (en) | Heteroaryl-fused macrocyclic pyrimidine derivatives | |
| CN111417628A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物、其盐及其合成方法 | |
| AU777092B2 (en) | Bicyclic vasopressin agonists | |
| SK286686B6 (sk) | Substituované imidazoly a tiazoly, farmaceutická kompozícia s ich obsahom a ich použitie | |
| MXPA05006582A (es) | Complejos de e-2-metoxi -n-(3 -{4-[3 -metil-4 -(6-metilpiridin -3- iloxi) fenilamino] quinazolin -6-il} alil) acetamida, su procedimiento de produccion y uso. | |
| EP1086095B1 (en) | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors | |
| CA1211107A (en) | Benzazepine derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |